No Data
No Data
Trending Stocks Today | VSee Health Soars 44.51% Post-Market
GRI Bio Shares Are Trading Higher After the Company Announced It Presented Preclinical Data Highlighting GRI-0621's Ability to Inhibit Invariant Natural Killer T Cell Activity.
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (INKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
Express News | Ascendiant Capital Initiates Coverage On GRI Bio With Buy Rating, Announces Price Target of $12
GRI Bio Analyst Ratings
GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis
No Data
No Data
Rockhoundj : I think $1 is coming
humorous Kiwi_5134 OP : $1.40